RWA
ACAD icon

Ropes Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Ropes Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-49
Closed -$3K – 249
2020
Q4 		$3K Buy
+49
New +$2.43K ﹤0.01% 593

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Ropes Wealth Advisors's ACAD Position: Q1 2021 in Review

Ropes Wealth Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 49 shares — an estimated $3K sold.

Ropes Wealth Advisors first reported a position in ACAD in Q4 2020 and held it in 1 quarter. The position peaked at $3K in Q4 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

  • Ropes Wealth Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Ropes Wealth Advisors sold 49 Acadia Pharmaceuticals shares in Q1 2021, an estimated $3K.
  • Ropes Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Ropes Wealth Advisors's Acadia Pharmaceuticals position peaked at $3K in Q4 2020.
  • 272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Ropes Wealth Advisors's 13F filing for Q1 2021, filed 12 May 2021.